Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
IQ-AI Limited ( (GB:IQAI) ) just unveiled an announcement.
IQ-AI Limited’s subsidiary, Imaging Biometrics LLC, has announced promising preliminary results from a Phase 1 study of oral Gallium Maltolate (GaM) in patients with recurrent/refractory glioblastoma. The study, nearing completion, shows early signs of efficacy with an overall survival of 32 months from initial diagnosis, significantly higher than the typical 8-9 months for glioblastoma patients. Despite the progression-free survival being similar to current standards, the prolonged overall survival suggests potential anti-tumor activity of GaM, marking a positive development for the company and its stakeholders.
More about IQ-AI Limited
IQ-AI Limited, through its wholly-owned subsidiary Imaging Biometrics LLC, focuses on delivering quantitative imaging platforms and therapeutics to enhance the diagnosis and treatment of patients. The company is committed to transforming clinical practices by providing advanced imaging solutions.
YTD Price Performance: -42.86%
Average Trading Volume: 770,569
Technical Sentiment Signal: Strong Buy
Current Market Cap: £1.94M
For detailed information about IQAI stock, go to TipRanks’ Stock Analysis page.